ProPhase Labs Forms Clinical Advisory Board to Advance BE-Smart Esophageal Cancer Diagnostic Platform
Key Insights
ProPhase Labs (search) has established a Clinical Science Advisory Board to accelerate commercialization of its BE-Smart (search) molecular test for esophageal disease (search) detection and cancer risk management.
The BE-Smart (search) test measures real-time protein activity using mass spectrometry from a single tissue section, delivering results in under 7 days with seamless integration into existing clinical workflows.
The company targets a $7-14 billion market opportunity with approximately 7 million annual endoscopies performed on patients at risk of esophageal cancer (search) in the United States.
ProPhase Labs (search) Inc. (NASDAQ: PRPH) announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-Smart (search) molecular test for esophageal disease (search). The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer (search) risk.
Market Opportunity and Commercial Potential
The company has identified a substantial market opportunity in esophageal cancer (search) diagnostics. According to CEO Ted Karkus, the target market encompasses roughly 7 million endoscopies performed each year in the United States alone on patients at risk of esophageal cancer, with a reimbursement goal of $1,000 - $2,000 per test. This translates to a $7 - $14 billion target market that Karkus describes as "virtually untapped."
"We believe BE-Smart (search) has the potential to redefine how some severe esophageal disease (search) progressing to cancer is detected and managed," said Karkus. "This advisory board brings together the scientific leadership, clinical insight, and operational expertise needed to scale this innovation and bring it into widespread clinical use."
Technical Advantages and Clinical Integration
BE-Smart (search) offers distinct advantages in the molecular diagnostics landscape for esophageal disease (search). Unlike imaging-based or DNA methylation approaches, BE-Smart measures real-time protein activity, capturing the dynamic biological signals of disease progression. The test requires only a single 10 μm FFPE biopsy section, minimizing tissue burden and simplifying laboratory workflows.
The diagnostic platform integrates seamlessly into existing endoscopy and pathology procedures, delivering results in under 7 days with no added complexity for providers. Its versatility extends beyond progression prediction, helping stratify risk across a spectrum of patients with GERD (search) and Barrett's Esophagus (search), including those with non-dysplastic or indefinite dysplasia, areas where current tools often fall short.
Competitive Positioning and Technology
The BE-Smart (search) test builds on progress made by existing technologies in the esophageal diagnostics space. While TissueCypher (search) (Castle Bioscience (search)) has introduced pathologists and gastroenterologists to tissue-based molecular insights, and EsoGuard (search) (Lucid Diagnostics) offers less invasive disease monitoring, BE-Smart positions itself as a next-generation approach combining real-time biological precision with streamlined clinical integration.
The test's high-throughput, multiplexible design, enabled by advanced mass spectrometry, allows for deep protein-level analysis from minimal tissue input. This approach is designed to deliver both depth of insight and operational ease across a wide range of care settings.
Intellectual Property Protection
The BE-Smart (search) molecular test is protected by robust intellectual property centered on eight key proteins (search) identified as critical biomarkers for esophageal adenocarcinoma (search) progression. ProPhase Labs (search) has secured exclusive patents covering the proprietary methods for detecting and analyzing the expression of these proteins, which are uniquely associated with the molecular mechanisms driving esophageal disease (search) progression to malignancy.
Advisory Board Leadership
The advisory board includes Dr. Joe Abdo, the inventor of the BE-Smart (search) test and a nationally recognized leader in molecular oncology with over 15 years of experience in cancer diagnostics, translational research, and biotech business development. Dr. Abdo has authored more than 30 peer-reviewed publications and teaches graduate-level courses at Georgetown University Medical Center. He plans to leverage his relationships with academia, the Mayo Clinic GI Path department, KUMC gastroenterology, and key opinion leaders in the esophageal cancer (search) space.
Also joining the advisory board is James McCullough, founder and CEO of Renalytix (search) and former Chief Executive Officer of Exosome Diagnostics (search) Inc., a pioneer in liquid biopsy diagnostics. McCullough brings decades of leadership experience in precision medicine, having successfully launched and scaled diagnostic technologies in both public and private sectors.
Clinical Validation and Regulatory Progress
A full data package detailing the test's validation and clinical utility is currently under peer review. The latest BE-Smart (search) clinical validation manuscript, "Assessing Risk of Progression in Barrett's Esophagus (search) Using a Mass-Spectrometry-Based Proteomic Panel," is under review at the Journal of Clinical Gastroenterology and Hepatology, with a preprint potentially available in the coming weeks.
The Clinical Science Advisory Board will focus on accelerating clinical adoption, guiding payer education, and supporting evidence development and regulatory advancement as the company prepares for its initial commercial launch.